Psoriasis

A large cohort study finds elevated risks of sepsis, genitourinary infections, and longer hospital stays in patients with hidradenitis suppurativa (HS).

SB17, a new ustekinumab biosimilar, demonstrates comparable efficacy and safety for psoriasis and psoriatic arthritis, enhancing patient experience and convenience.

National Psoriasis Awareness Month offers an opportunity to examine how advances in systemic therapy, combined with patient-centered care models, are reshaping the treatment landscape.

Long-term exposure to pollutants was linked to higher psoriasis risk, especially in people with genetic predispositions.

A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab over 2 years.

Interclass biologic switching can improve outcomes, but it also increases infection rates.

Clearer information on fertility, heredity, and medication use is necessary during family planning for patients with psoriasis.

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both psoriasis and coronary artery disease.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals with diverse skin tones.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council guidelines.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those with higher BSA, a new study finds.

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared with the general population.

Ustekinumab offers superior itch relief for severe psoriasis compared with guselkumab, new data show.

Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.

The impact of psoriasis on quality of life goes beyond clinical measures, such as psoriasis area severity index (PASI) and body surface area (BSA), a study finds.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.

Biologics for psoriasis had lower drug survival in women compared with men, according to one study.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving quality of life in patients with moderate to severe scalp psoriasis.